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Epithelial malignancies are effectively treated by
antiangiogenics; however, acquired resistance is a
major problem in cancer therapeutics. Epithelial tu-
mors commonly have mutations in the MAPK/Pi3K-
AKT pathways, which leads to high-rate aerobic
glycolysis. Here, we show how multikinase inhibitor
antiangiogenics (TKIs) induce hypoxia correction in
spontaneous breast and lung tumor models. When
this happens, the tumors downregulate glycolysis
and switch to long-term reliance on mitochondrial
respiration. A transcriptomic, metabolomic, and
phosphoproteomic study revealed that this meta-
bolic switch is mediated by downregulation of
HIF1a and AKT and upregulation of AMPK, allowing
uptake and degradation of fatty acids and ketone
bodies. The switch renders mitochondrial respiration
necessary for tumor survival. Agents like phenformin
or ME344 induce synergistic tumor control when
combined with TKIs, leading to metabolic synthetic
lethality. Our study uncovers mechanistic insights
in the process of tumor resistance to TKIs and may
have clinical applicability.
INTRODUCTION
Epithelial tumors commonly harbor oncogenic alterations in the
MAPK and Pi3K-AKT axes (Kandoth et al., 2013). These path-
ways drive aerobic glycolysis, the main source of energy and up-
take of ‘‘building blocks’’ for tumor growth (Foster et al., 2012;
Garcia-Cao et al., 2012; Lunt and Vander Heiden, 2011; Ying
et al., 2012). Pathologic tumor angiogenesis, which is linked to
interstitial hypoxia, supports enhanced glycolysis (Jain, 2005;
Ostergaard et al., 2013). Extensive work by Rakesh Jain and
Robert Kerbel shows that, at least in some cases, antiangiogenicCell
This is an open access article under the CC BY-Nagents may elicit their effect by reversting the abnormal
physiology of tumor blood vessels (caused by a disequilibrium
between pro- and antiangiogenic factors), normalizing tumor
oxygenation, and correcting other features that support tumor
progression (Jain, 2005, 2013; Kerbel, 2006). Acquired resis-
tance to antiangiogenics is a major problem in cancer thera-
peutics, since antiangigoenic agents are the most widely used
biologic agents in oncology and are approved by the Food and
Drug Administration (FDA) for use against breast, colorectal,
lung, ovarian, kidney, and liver cancer, among other malig-
nancies. Several resistance mechanisms, mainly involving spe-
cific compensatory signaling loops, have been described and
have potential clinical impact due to newly developed com-
pounds that target them (Lu et al., 2012; Oliner et al., 2004). How-
ever, the effects of the pharmacologic modulation of multiple
kinases, plus the alteration of oxygen and nutrient levels second-
ary to the disruption of blood vessel homeostasis, may induce
pleiotropic adaptive responses involving several pathways inter-
twined across multiple -omic levels. We hypothesize that, in
cases in which antiangiogenics lead to hypoxia normalization,
chronic high-rate glycolysis is offset and tumors might switch
to an alternative metabolic source. If this alternative source
were essential for tumor survival, it would open up therapeutic
opportunities.
Two main types of antiangiogenics have been developed:
monoclonal antibodies (mAbs) and multi-tyrosine-kinase inhibi-
tors (TKIs). Among the TKIs, sorafenib and sunitinib have been
tested the most extensively in phase III trials, but, aside from
liver/kidney cancers, their therapeutic effects have not been pos-
itive. Both drugs yielded negative phase III trials in lung (Heist
et al., 2014; Scagliotti et al., 2010) and breast cancer (Baselga
et al., 2013; Crown et al., 2013). Nintedanib is a recently devel-
oped TKI that has recently been approved based on a positive
trial in lung cancer (Reck et al., 2014). Promising results have
also been observed in breast cancer (Quintela-Fandino et al.,
2014). Nintedanib and dovitinib, another TKI with a very similar
profile, differ from older TKIs by having lower KM values against
pro-angiogenic kinases. Theoretically, TKIs, since they act overReports 15, 2705–2718, June 21, 2016 ª 2016 The Author(s). 2705
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
several angiogenic axes, could be more likely to reverse the
abnormal balance between the plethora of pro- and antiangio-
genic factors that cause tumor vascular abnormality (Jain,
2005, 2013) comparedwith agents that target a single pro-angio-
genic factor. Several TKIs are under active development for
many malignancies. Thus, it is important to address the mecha-
nisms of acquired resistance against TKIs.
This study explores the mechanism of adaptation against
recently developed antiangiogenic TKIs in the realm of cancer
metabolism and the potential synthetic-lethal therapeutic impli-
cations that result. The effects of several TKIs (nintedanib and
dovitinib, and external validation of the findings with regorafenib)
are examined in breast and lung cancer models (genetically en-
gineered mouse models of cancer and tumor xenografts).
RESULTS
TKIs Oxygenate the Interstitium and Downregulate
Glucose Uptake while Inhibiting Tumor Growth
The PyMT breast cancer model was backcrossed to a pure
Friend virus B (FVB) background for ten generations, creating a
spontaneous breast cancer model with the characteristics de-
picted in Figure S1 (hormone-receptor positive, high replicative
fraction, and sensitive to tamoxifen), and which recapitulates
the phenotype of approximately one-third of the hormone-re-
ceptor positive tumors seen in the clinics. In this model, invasive
lesions were present at 4 weeks of age (Figure S1), and tumors
reached an average size of 100 mm3 at approximately 7 weeks
of age. The PyMT oncogene activates the MAPK and Pi3K-
AKT pathways (Figure S2A). This activation leads to high glucose
uptake (Figure S2B), which makes it a good model to study the
effects of TKIs in the Warburg effect.
Starting at 7 weeks of age (T0) we exposed mice to long-
term treatment with vehicle, nintedanib, or dovitinib. We used
B20-4.1.1 as the reference antiangiogenic agent. B20-4.1.1 is
a mAb with activity against human and murine VEGF that
substituted for bevacizumab in preclinical research in mice
(Liang et al., 2006). The animals were treated on a continuous
schedule, as in a clinical setting. The adaptive changes occurring
during treatment were monitored along a time course: T0, T1
(week 1 of treatment), and Tend. The efficacy parameter under
study was tumor growth inhibition (TGI) at the time when
vehicle-treated animals reached the humane euthanization
endpoint (Tend).
The two TKIs block human and murine VEGFR, PDGFR, and
FGFR families with similar KM values. To avoid the potential
confounding effects of FGFR1 blockade (a kinase implicated
in driving oncogenic addiction in 10% of breast cancers; Curtis
et al., 2012), the absence of FGFR1 expression in this model
was confirmed (Figure S1F).
Rapidly growing tumors are supported by abnormal vessels
(Jain, 2005), leading to hypoxia that triggers the transcriptional
program that fuels the Warburg effect (Jain, 2005; Ostergaard
et al., 2013). Both the TKIs and the reference antiangiogenic
agent B20-4.1.1 caused 60% TGI (Figure 1A) and affected
microvessel density in a similar manner (Figure 1B). However,
the TKIs normalized the vasculature (Figure 1C) and thus intra-
tumor hypoxia (Figure 1D). In comparison, tumors treated with2706 Cell Reports 15, 2705–2718, June 21, 2016B20-4.1.1 or vehicle showed progressively increased hypoxia
and vessel abnormality. Congruently with the decrease in hypox-
ia, the TKI-treated tumors showed decreased glucose uptake
(measured with 18F-FDG-PET ([18F]fluorodeoxyglucose [FDG]
micro positron emission tomography [PET]) during treatment
compared to tumors treated with vehicle (Figure 1E). Treatment
with B20-4.1.1 did not normalize the vasculature or hypoxia, and
glucose avidity was subsequently maintained similar to that for
untreated tumors (Figures 1C–1E).
Tumors that Become Normoxic Because of Exposure to
TKIs Switch to Mitochondrial Metabolism
Rapidly growing tumors increase aerobic glycolysis (i.e., War-
burg effect) due to oncogenic and tumor suppressor mutations,
resulting in tumor uptake of glucose to support biosynthesis of
macromolecules required for cell proliferation, which is further
supported by tumor hypoxia (Foster et al., 2012; Garcia-Cao
et al., 2012; Lunt and Vander Heiden, 2011; Ying et al., 2012).
Among the differences observed at the microenvironmental
level, how tumors with hyperactive PI3K/AKT and MAPK were
able to continue growing despite lack of hypoxia development
and a 2-fold decrease in glucose uptake under TKI treatment
was most interesting. The potential of tumor metabolism reprog-
ramming in animals treated with nintedanib was investigated,
using vehicle as a control and B20-4.1.1 as a reference antian-
giogenic. In subsequent experiments, B20-4.1.1-treated tumors
behaved like vehicle-treated tumors; data are not shown unless
required for experimental data layout, because the adaptive
changes regarding resistance to mAb antiangiogenic treatment
have been described elsewhere (Chung et al., 2013; Xu et al.,
2014).
We studied more than 320 metabolites and 40 metabolic
routes in 109 tumors in a gas chromatography/liquid chromatog-
raphy (GC/LC)-mass spectrometry (MS)-guided metabolomic
study. Tumor glucose concentration decreased over time in
both treatment groups; however, glycolysis metabolites like
glucose-6-phosphate and lactate were diminished in ninteda-
nib-treated tumors compared to vehicle (Figure 2A). Although
steady-state determinations do not allow inference of true meta-
bolic fluxes, these data suggest decreased glycolytic use of
glucose. Another feature of aerobic glycolysis is the fueling of
the pentose-phosphate shunt from glucose-6-P for biosynthetic
purposes (Lunt and Vander Heiden, 2011). End products of the
oxidative (ribulose) and nonoxidative phases (sedoheptulose-
7-phosphate, ribose-5-phosphate [R-5P], xylulose-5-phosphate
[X-5P]) of the pathway were also decreased in nintedanib-
treated tumors (Figure 2B). Decreased glycolysis could be
compensated by an increased mitochondrial tricarboxylic acid
(TCA) cycle. TCA uses pyruvate, ketones, and carnitine-bound
fatty acids as substrates. An almost 2-fold increase in intratumor
3-hydroxybutyrate and carnitine-bound end products of
b-oxidation acetylcarnitine and butyrylcarnitine concentration
were detected in tumors treated with nintedanib compared to
those treated with vehicle (Figure 2C).
In healthy tissues, mitochondrial use of these nutrients in-
creases during nutritional stress and is controlled by PPARa
transcription factors, which enhance transcription of lipolytic
and oxidative phosphorylation enzymes and induce fatty acid
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Figure 1. TKI Antiangiogenics Induce Normoxia and Decrease Tumor Glucose Avidity while Inhibiting Tumor Growth
(A) Tumor growth inhibition (TGI) exerted by nintedanib (64.6%), dovitinib (62.6%), or B20-4.1.1 (63.9%). n > 150 tumors per group.
(B) Microvessel density assessed both in the hypoxic (pimomidazole staining-positive) and normoxic (pimomidazole-negative) areas). The p value (t test) was
significant (<0.05) for the three treatment groups versus vehicle at T1 and Tend in the pimomidazole-negative areas.
(C) Decreased 10KD-dextran-FITC extravasation (red staining in the peri-vascular areas, evidenced by anti-CD31 staining, green) and stasis in the tumor
interstitium and vessel tortuosity, parameters that mirror vascular abnormality, were observed as TKI-treated tumors grew compared to vehicle.
(D) Progression of hypoxia (pimomidazole [dark-red] staining, arrowheads) and necrosis (asterisks) along the different treatments. The numbers represent the
percentage of the tumor area stained by pimomidazole or with necrosis.
(E) Tumor glucose uptake by FDG-PET was significantly lower over the long termwith nintedanib treatment (20%, p = 0.22 at T1;48.5%, p < 0.001 at Tend) and
dovitinib (48%; p = 0.012 at T1; 44%, p < 0.008 at Tend). n > 50 tumors per time point and group. Error bars, SEM.oxidation: PKA, which is activated by B2 receptor stimulation
and, in turn, activates the hormone-sensitive peripheral lipase;
and AMPK activation, a kinase that upregulates aerobic degra-
dation of nutrients (Soeters et al., 2012). A transcriptomic study
suggested that the same mechanisms, directed to increasemitochondrial metabolism, were set in motion in nintedanib-
treated tumors. A gene set enrichment analysis of the tumor
transcriptome showed upregulation of aerobic catabolism path-
ways and PPAR signaling in nintedanib- versus vehicle-treated
tumors (Figure 3A), supporting the enzymatic processes behindCell Reports 15, 2705–2718, June 21, 2016 2707
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Figure 2. Downregulation of Glycolysis and Pentose-Phosphate Shunt and Increased Metabolites Targeted for Mitochondrial Degradation
The boxplots (A–C) represent the following: raw area counts for each species were log-transformed and rescaled to have amedian equal to 1 (calculated from the
acquisition spectra of 109 tumors). For each tumor, a ratio was calculated versus the median. Boxplots with the ratios of 14–16 tumors per time point and
condition were plotted for each species. +, mean value; —, median value; o, extreme data point. Because of the asymmetric nature of the data distribution,
median values are more representative than means.
(A) Glycolytic intermediates.
(B) Intermediates of the pentose-phosphate pathway. R-5P and X-5P are isomers and are in equilibrium, thus determined inseparably.
(C) Metabolites targeted for mitochondrial degradation and O2-consumption-coupled ATP generation.the metabolic switch. To increase robustness, we examined
whether congruent signalosome changes occurred. A MS-
based phosphoproteomic assay was conducted using isobaric
tagging and approximately 1,000 phospho-peptides were iden-
tified. Using MaxQuant, the putative kinases responsible for
the phosphorylation of each residue identified were predicted.
Examination of the clustering of the phosphorylation status of
AMPK1/2 and PKA substrates into random or real patterns sug-
gested that the activity of both was increased with nintedanib
treatment (Figure 3B). Eighteen phosphorylated AMPK1/2 sub-
strates were identified, eight of which showed increased phos-
phorylation at Tend in nintedanib-treated animals compared to
tumors treated with either vehicle or B20-4.1.1 (Figure 3B, left
panel; Table S1; B20-4.1.1 data are shown as the generation
of hypothetical random clusters considered three-way patterns).
Eleven of those 18 substrates showed increased phosphoryla-
tion from T0 to T1 to Tend with nintedanib treatment (Figure 3B,2708 Cell Reports 15, 2705–2718, June 21, 2016middle panel, and Table S2). In addition, 288 of 590 identified
PKA substrates showed increasing phosphorylation from T0 to
T1 to Tend with nintedanib treatment (Table S3). Among the
AMPK- and PKA-regulated substrates, the hydroxypyruvate
reductaseGlyr1, which is known to promote b-oxidation in plants
(Pracharoenwattana et al., 2010), and IRS-1 (serine/threonine
phosphorylation antagonizes the insulin-induced tyrosine-phos-
phorylation events involved in glucose uptake and anabolic
pathways [Li et al., 2008]) were identified, respectively.
Taken together, the presented data suggest that tumor meta-
bolism was reprogrammed in response to TKIs, with mitochon-
drial metabolism increasing under the control of PPAR-a,
AMPK, and PKA activation in response to decreased glycolysis.
We focused on finding further mechanistic proof of themetabolic
switch and on demonstrating that TKIs induced increased mito-
chondrial respiration, by conducting a mechanistic validation
study with both agents.
AB
Figure 3. Reprogramming at the Transcriptomic and Phosphoproteomic Levels Supports the Metabolic Switch
(A) Gene enrichment analysis plots showing activation of pathways involved in aerobic metabolism in Tend of nintedanib- versus vehicle-treated tumors. NES,
normalized enrichment score. The q value is the false discovery rate.
(B) Phosphorylation levels of predicted AMPK and PKA substrates.As shown, TKIs prevented the development of hypoxia. HIF1a
is the main controller of the response to hypoxia, and the inhibi-
tion of mitochondrial respiration and upregulation of glycolysis
are two of its main downstream effects. Vehicle-treated tumors
showed increased HIF1a levels with tumor progression, but
HIF1a was undetectable in TKI-treated tumors of the same
size (Figure 4A). The PyMT oncogene downregulates the func-
tion of phosphatases at the Pi3K/AKT and MAPK levels, which
is associated with high glucose avidity. Thus, resilient activation
of both pathways, despite the environmental conditions, would
be expected. Such was the case for phospho-ERK (Figure 4B).
However, congruent with the phosphorylated IRS-1 residue
identified by MS and implicated in downregulating insulin-driven
IGF-1R signaling, AKT phosphorylation was decreased in TKI-
treated tumors (Figure 4C). The ATP sensor AMPK requiresser-172 phosphorylation for activation of its downstream
cascade leading to downregulation of glycolysis and upregu-
lation of mitochondrial metabolism. Consistent elevation of
p-AMPK was observed in both TKI-treated tumors (Figure 4D)
(these tumors were LKB1-positive; Figure 4E). Phospho-CREB,
a substrate that translates PKA activity, showed increased phos-
phorylation in TKI-treated tumors (Figure 4F). In addition, the
transcription factor PPARa was also upregulated in TKI-treated
tumors (Figure 4G). The immunohistochemistry data shown in
Figure S3A show that the observed changes occur in the tu-
mor-epithelial compartment.
Taken together, the presented data suggest that under
chronic treatment with antiangiogenic TKIs, tumors remain
normoxic, which abrogates HIF1a stabilization. The lack of
HIF1a together with the decreased AKT signaling contributesCell Reports 15, 2705–2718, June 21, 2016 2709
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Figure 4. Signaling Changes Accounting for Decreased Glycolysis and Increased Mitochondrial Metabolism during the Adaptive Response
against TKIs
Immunoblots of lysates from tumors dissected at Tend from mice chronically treated with vehicle, dovitinib, or nintedanib. Tumors were obtained from the upper
mammary glands from three different animals per condition.
(A) HIF1a staining.
(B) pERK and total ERK staining.
(C) pAKT and total AKT staining.
(D) pAMPK and total AMPK staining.
(E) LKB1 staining; a positive and a negative control lysate were included for LKB1.
(F) pCREB and total CREB staining.
(G) PPARa staining. Actin or vinculin were used as loading controls depending on the molecular weight of the probes.
2710 Cell Reports 15, 2705–2718, June 21, 2016
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(legend on next page)
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to the decreased glycolysis output. This leads to relative nutri-
tional stress, evidenced by AMPK, PKA, and PPAR-a activation.
The -omic determinations suggest increased mitochondrial
metabolism, which could compensate for this tumor nutritional
stress. Thus, we sought to determine the source of nutrients
for mitochondrial metabolism (elevated concentration of fatty
acids and ketones found in tumors by MS) and to prove the
increased mitochondrial respiration in vivo in this system.
Ketone bodies are synthesized in the liver, and, unless an indi-
vidual undergoes nutritional starvation, baseline production re-
mains stable and blood levels barely change (Soeters et al.,
2012). Expression of the enzymaticmachinery accounting for ke-
tone synthesis in tumors was not observed (data not shown).
Blood ketone levels remained stable over time (Figure 5A); how-
ever, a >2.5-fold upregulation of the ketone-body transporters
MCT1 and four in TKI-treated tumors was detected, compared
to vehicle-treated tumors, coupled with a >4-fold increase in
the levels of ACAT1, the enzyme that allows re-use of ketone
bodies as mitochondrial substrates (Figure 5B). These observa-
tions suggest active uptake of ketones from the background
pool synthesized in the liver and released to the bloodstream.
Because of the relative small contribution of the tumor compart-
ment to body weight (less than approximately 1/30 at Tend), the
tumor-restricted starvation was probably not sufficient to pro-
duce systemic ketosis and cause blood level fluctuations of
these species.
Regarding fatty acids, plasma triglycerides were measured
and no differences were found among the treatment groups (Fig-
ure 5C). However, tumor histologic analysis revealed a differen-
tial pattern for lipidic deposits (hematoxylin/eosin, Figure 5D; or
perilipin staining, Figure 5E) between TKI- or vehicle-treated
tumors. Throughout the treatment time, adipose deposits
remained stable (10%–15% of the tumor section) in vehicle-
treated tumors, whereas they almost disappeared with TKI treat-
ment. In addition, increased levels of the fatty acid transporters
FABP3, CAV1, and SLC27A1/A2 and the lipases PNPLA2 and
3 were found in tumors (Figure 5F), coupled with an 4-fold up-
regulation of CPT1B (Figure 5F), which shuttles the carnitine-
bound species committed for mitochondrial degradation into
the mitochondrial matrix. Taken together, these data suggest
that the tumor cells took up fatty acids from the surrounding
adipocytes. The immunohistochemistry showed in Figure S3B
show that the upregulation of ketone bodies and fatty acids
transporters and enzymes implicated in their degradation
occurred in the tumor epithelial compartment.
In an attempt to demonstrate increased mitochondrial meta-
bolism in tumors, an enzymohistochemical assaywas performedFigure 5. Increased Ketone Bodies and Fatty Acids Transporters and
Adipose Deposits, in Tumors from TKI-Treated Animals
(A and C) Plasmatic levels of ketones and fatty acids did not significantly differ b
(B) qRT-PCR values of MCT1, MCT4, and ACAT1 normalized to T0 tumors. Asteris
**p < 0.001, ***p < 0.0001.
(D) H&E staining revealed a solid histologic pattern, with scarce adipose (arrowh
(E) Immunohistochemistry (IHC) staining of perilipin confirmed a decrease (13.8%
TKI-treated tumors. The intracellular (epithelial) lipid droplets also decrease with
(F) qRT-PCR of fatty acid transporters, lipases, and mitochondrial shuttle in ve
differences between samples: *p < 0.05, **p < 0.001, ***p < 0.0001.
2712 Cell Reports 15, 2705–2718, June 21, 2016to measure respiratory activity on fresh tissue (Taylor et al.,
2003). Succinate dehydrogenase (SDH) or complex II is an
enzyme complex bound to the inner mitochondrial membrane
that catalyzes the eighth step of the Krebs cycle (oxidation of
succinate to fumarate), while reducing ubiquinone to ubiquinol
(second step of electron-transport chain). The reaction trans-
lates to increased aerobic activity (dark blue versus light or no
staining). The assay, performed in fresh tumors right after sacri-
fice at T1 and Tend, showed increased mitochondrial metabolism
with either TKI, even at early time points (Figure 6A). Of note, TKI-
treated tumor tissue had more intense staining than striated
muscle fibers that were included in the histologic preparations
as positive control and were located adjacent to the breast
tumors.
We measured the oxygen consumption rate of cells freshly
extracted from tumors treated until Tend with either vehicle or
TKI, using the Seahorse Mito-Stress test. In both cases (Figures
6B and 6C), the coupled respiratory capacity was2-fold higher
in tumors treated with TKI versus vehicle. Phenformin, a bigua-
nide that blocks mitochondrial respiration through inhibition of
complex I (El-Mir et al., 2000), suppressedmitochondrial respira-
tion at 1,000 nM (Figure 6B).
The Switch to Mitochondrial Metabolism Is Necessary
for Tumor Survival: Metabolic Synthetic Lethality
If the increased mitochondrial metabolism was relevant as an
energy source in the context of TKI treatment, then the pharma-
cologicmodulation ofmitochondrial respirationmight be ineffec-
tive if used as monotherapy. However, it should enhance the
effects of the TKIs. We sought to prove the pro-survival role of
mitochondrial metabolism during the adaptive tumor response
to chronic treatment with TKI antiangiogenics.
Tumors were treated for 4 weeks with nintedanib and then the
animals were exposed to a short course (3 days) of vehicle or
phenformin. The administered dosage (300 mg/kg per day) of
phenformin was observed to reverse the ‘‘mitochondrial pheno-
type’’ induced by nintedanib treatment (Figure 6D). Knowing that
phenformin was able to induce the expected pharmacodynamic
effects, the TGI properties of the various combinations predicted
by our model were tested. Phenformin, despite pharmacody-
namic proof of activity (suppression of respiration ex vivo
[Figure 6B] and in vivo [Figure 6D]), was not effective when
administered in monotherapy (17% TGI; p = 0.88). However,
phenformin had a synergistic effect with nintedanib (TGI
increased from 64% to 86%, p = 0.004). The addition of phen-
formin to dovitinib was synergistic as well, increasing the TGI
from 62% to 82% (p = 0.003), suggesting TKI-induced tumorShuttles for Mitochondrial Degradation, Coupled with Decreased
etween vehicle- and TKI-treated animals.
ks were used for indicating significant differences between samples: *p < 0.05,
eads) deposits in TKI-treated tumors versus untreated.
of tumor surface area to 2.6%; p = 0.012) in fat depots (arrowheads) with time in
nintedanib/dovitinib treatment compared to vehicle-treated tumors.
hicle- and TKI-treated animals. Asterisks were used for indicating significant
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Figure 6. Evidence of Continuous, Long-Term, Increased Mitochondrial Respiration In Vivo in Tumors Treated with TKIs and Metabolic
Synthetic Lethality
(A) The SDH activity in tumor cells (arrowheads) or striated muscle (squares, included as positive controls) is shown. The increased activity in tumor cell was
evident from 1 week of treatment and was maintained for more than 2 months.
(B and C) Oxygen-consumption rate from nintedanib- and dovitinib-treated tumors versus vehicle; respiration was suppressed by phenformin.
(D) In vivo pharmacodynamic effects of phenformin: animals treated for 4 weeks with nintedanib were then treated for 3 days with vehicle (left) or phenformin
(right), showing a dramatic decrease of SDH activity in tumors in the latter case.
(E) Tumor growth inhibition with phenformin or either TKI alone or in combination. n > 50 tumors per group; error bars, SEM.
(F) Using the same treatment schedule as in (D), the 3-day course of phenformin was sufficient to induce an average 73% reduction in tumor size (p = 0.012), what
we termed ‘‘metabolic synthetic lethality,’’ whereas tumors from animals receiving a 3-day course of vehicle experienced a slight growth. The chart represents the
average tumor size before and after 3 days of vehicle of phenformin (n = 12).
(legend continued on next page)
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dependence on mitochondrial respiration (Figure 6E). These
data suggest that although mitochondrial metabolism can be
pharmacologically inhibited with phenformin, it is only necessary
for tumor survival when glycolysis has been downregulated by
chronic antiangiogenic TKI treatment.
In addition, tests were conducted to determine whether a
sequential, rather than concurrent, schedule would have more
intense therapeutic effects; that is, whether adding phenformin
after the mitochondrial phenotype has been ‘‘induced’’ would
be more effective. Dependence on mitochondrial metabolism
was induced by priming the tumors with nintedanib treatment
(4 weeks) and then exposing them to phenformin or vehicle for
only 3 days. The therapeutic effects on established large tumors
are shown in Figure 6F. This suggests that mitochondrial activity
is essential for replacing the decrease in aerobic glycolysis and
for allowing tumors to withstand prolonged treatment with anti-
angiogenic TKIs. Other aerobic metabolism inhibitors (PPARa-
and beta-blockers) increased the therapeutic effects of the
TKIs (Figure S4) as well.
According to this model, phenformin should not be effective
when added to the reference antiangiogenic treatment (B20-
4.1.1), because it does not induce hypoxia correction. The com-
bination lacked therapeutic effects (Figure 6G).
Finally, phenformin has been reported to directly influence
endothelial cell survival (Orecchioni et al., 2015). It has also
been shown that phenformin canmodulate HIF1a and VEGF pro-
duction (Hsu et al., 2013; Martin et al., 2012). Such effects could
interfere with the observedmetabolic synthetic lethality. Accord-
ing to our data, none of those effects were a major contributor to
the observed therapeutic effects of the combinations (Figure S5).
On the other hand, the observed metabolic response was not
part of a TKI-induced tumor cell-autonomous response (Fig-
ure S6), since chronic treatment with TKIs did not induce
changes in maximum oxygen consumption rate (Figure S6A),
or AKT, HIF, AMPK, or PPAR-alpha levels (Figure S6B). In addi-
tion, chronic treatment with TKIs did not sensitize the BRL1468
cell line to phenformin in vitro, as opposed to the observed
effects in vivo (Figure S6C).
The Therapeutic Synergy Is Observed with the TKI
Regorafenib and the Mitochondrial Inhibitor ME344 and
Can Be Extended to Other Cancer Models
The therapeutic effects of using a different mitochondrial inhibi-
tor or an additional TKI were tested in the PyMT model. The re-
sults in Figure 7A show that when ME344, another clinical-grade
mitochondrial inhibitor (Bendell et al., 2015) that lacked efficacy
in monotherapy (TGI = 7.4%) is used instead of phenformin,
the effects are also synergistic (nintedanib: 64%; nintedanib +
ME344: 92%; p < 0.05). Regorafenib, a TKI recently approved
for colorectal cancer, lacked efficacy in monotherapy. However,
the combination with ME344 abrogated tumor growth (TGI
increased from4.5% to 88%; p < 0.05). ME344 induced similar
effects to those of phenformin in mitochondrial respiration (Fig-(G) Lack of effect of adding phenformin to B20-4.1.1. TGIs: phenformin: 17%;
developed faster growth tumors than vehicle-treated tumors in some occasions
sacrifice even though the average size was lower than 1,000 mm3, explaining the
the treatment groups. n > 50 tumors per group; error bars, SEM.
2714 Cell Reports 15, 2705–2718, June 21, 2016ures S7A and S7B), and the mechanisms by which regorafenib
induced sensitivity to ME344 were similar to those observed
for the remaining TKIs (Figures S7C–S7F).
In order to test the applicability of the observed phenomenon,
the therapeutic tests were extended to include two lung cancer
models because nintedanib has recently been approved by the
FDA for the treatment of this disease on the basis of improved
overall survival in a phase III trial (Reck et al., 2014).
Pulm24 is a lung-cancer-patient-derived xenograft (PDX). This
PDX is an adenocarcinoma of the lung, mutant for KRAS and
wild-type for EGFR. Nintedanib alone was able to significantly
delay tumor growth (Figure 7B). Similar to the PyMT model,
nintedanib caused a profound inhibition of glucose uptake
measured by FDG-PET (Figure 7C). Phenformin alone did not
show antitumor effect, but the combination of nintedanib
plus phenformin abrogated tumor growth, as predicted by our
hypothesis (Figure 7B).
The Lewis lung carcinoma (LLC) model is the most (primarily)
resistant of the models commonly used for testing the activity
of new drugs, especially those with antiangiogenic properties
(Nisancioglu et al., 2010; Shojaei et al., 2007). This model was
considered interesting for two reasons: first, because a signifi-
cant percentage of patients have primary resistance to this
drug class as well; and second, because albeit transplantable,
it is a spontaneous cancer model. The LLC model grows
extremely rapidly, causing local wounds and ulcerations at the
heterotopic graft site. According to our Institutional Animal
Welfare Committee rules, the animals have to be sacrificed at
this point, and pictures from ulcerations cannot be shown.
Thus, survival curves (determined by the ulceration-driven sacri-
fice dates) aremore illustrative than tumor size growth curves. As
expected, nintedanib alone lacked therapeutic effect (so did
phenformin; Figure 7D). Nintedanib decreased glucose uptake
as well (Figure 7E). As expected, phenformin added to ninte-
danib prolonged median overall survival by >40% (log-rank p <
0.001; Figure 7D).
DISCUSSION
These findings link acquired resistance to a powerful anticancer
drug class with aberrant cancer metabolism. The data show that
under selective pressure tumor plasticity allows sustained tumor
growth over the long term despite exposure to antiangiogenic
TKIs, but it renders mitochondrial metabolism necessary for
survival (model depicted in Figure 7F). In the cancer metabolism
program, the Warburg effect is considered a hallmark of cancer,
and the pentose-phosphate pathway and high TCA activity
are essential for tumor growth glycolysis (Foster et al., 2012;
Garcia-Cao et al., 2012; Lunt and Vander Heiden, 2011; Ying
et al., 2012). However, in our model, micro-environmental
changes induced by antiangiogenic TKIs are followed by a
response similar to that observed in healthy tissues during nutri-
tional stress (Soeters et al., 2012): downregulation of glycolysisB20-4.1.1: 61%; combination: 64% (p = 0.645). Phenformin-treated animals
(one or two tumors per animal out of six to eight growing lesions), mandating
reduction in average growth size compared to vehicle but earlier termination of
Figure 7. Metabolic Synthetic Lethality Is Observed with Different Agents and Is Extended to Lung Cancer Models
(A) Tumor growth of PyMT tumors treated with vehicle, nintedanib, regorafenib, ME344, or either TKI plus ME344.
(B) TGIs (calculated at T = 8 weeks, Tend of phenformin): nintedanib: 58%; phenformin: 10%; nintedanib + phenformin: 80% - synergistic (p = 0.028).
(C) FDG-PET of nintedanib-treated Pulm24 xenografts.
(D) Kaplan-Meier survival plots; p < 0.001 (log-rank) nintedanib versus nintedanib+phenformin; median survival time: 14 versus 20 days.
(E) Tumor glucose uptake by FDG-PET was significantly lower over the long term with nintedanib-treated LLC (52%, p = 0.0026). n > 50 tumors per group; error
bars, SEM.
(F) Schematics of antiangiogenic-induced metabolic changes. Vehicle-treated tumors mainly relied on glycolysis. The antiangiogenic treatment with TKIs
normalized the tumor vasculature and decreased hypoxia, decreasing the glycolytic flux. In turn, mitochondrial metabolism increased and sustained tumor
growth long term. However, in these conditions, the ability to switch from one metabolic source to another was impaired and rendered the mitochondrial
metabolism essential for tumor survival, evidenced by the effects of several mitochondrial metabolism inhibitors in combination with the TKIs.
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(mediated through decreased HIF1a and AKT signaling); activa-
tion of AMPK, PPARa, and PKA; uptake of ketones and fatty
acids from the bloodstream elicited by increased expression of
transporters; and upregulation of mitochondrial metabolism.
When one energy source (glycolysis) is pharmacologically
limited, the tumors become vulnerable to the inhibition of the
other (mitochondrial metabolism). Pharmacological blockers of
the nutritional stress response (phenformin and ME344) can
abrogate mitochondrial respiration and tumor growth in this sit-
uation, which we have termed ‘‘metabolic synthetic lethality.’’
Priming with antiangiogenic treatment, rather than administering
concurrent treatment, shows the most intense therapeutic ef-
fects (Figure 6F). Inhibitors of PPARa (GW6471 [Figure S4A]) or
PKA activation (propranolol [Figure S4B]) also enhance the TGI
effects of the TKIs, which suggests a possible mechanistic link
between these two signaling nodes and the adaptive mitochon-
drial response in this context. Because of the lack of specific
inhibitors of ketone bodies degradation, we cannot address
the relative contribution of this metabolic source to the meta-
bolic adaptation. The observed metabolic synthetic lethality is
completely non-cell autonomous, according to the in vitro
data; the ultimate reason for the synthetic lethality in vivo is un-
clear but likely secondary to the changes induced by the TKI in
the levels of oxygen and glucose in the tumor microenvironment.
Study conclusionsabout angiogenesis in translational oncology
have sometimes been contradictory, probably because the
investigations rely on different models, therapeutic schemes,
drug classes, or agents. Angiogenesis is a complex process,
andunderstanding themechanismsof resistancewith therapeutic
purposes depends on the mechanism of action of the specific
agent under study and the tumor type. The model used for study
may also be a factor. For example, xenograft models differ from
spontaneous cancer models in that the former lacks natural tu-
mor growth kinetics or immune system, an important regulator
of angiogenesis; interspecies stromal interaction may be a
confounding factor as well (Sharpless and Depinho, 2006). In
addition, the tumor evolves over time as the balance between
pro- and antiangiogenic factors inside the tumor changes, and
thus the effect of an antiangiogenic drug may tip that balance
in different directions depending on the time point (Jain, 2005).
In another study, we have observed that dovitinib induces nor-
moxia in several pancreatic PDXs, but hypoxia in others (Hernan-
dez-Agudo et al., 2016). Along similar lines of thought, there is a
study reporting hypoxia in various xenografts that were exposed
to nintedanib (Kutluk Cenik et al., 2013), an effect that we repro-
duced, for example, with the MDA-MB-231 breast cancer cell
line (data not shown). This heterogeneity in the type of interstitial
response may be caused by a great inherent variability in the
concentration of pro- and anti-angiogenic factors in different
tumors, causing a unique ‘‘angiogenic environment’’ in each
tumor type, or by the affinity and KM of the drugs for different
angiogenic targets. However, at least in a fraction of cases the
exposure to antiangiogenic treatment may lead to a decrease
in glucose avidity and glycolysis. Similarly to the findings by
DePinho and Draetta following KRAS ablation in a KRAS-driven
model (Viale et al., 2014), we have described how the tumors can
rely long term on mitochondrial respiration in vivo instead of on
the Warburg effect. These observations are of applicability in2716 Cell Reports 15, 2705–2718, June 21, 2016clinical trials; nintedanib, regorafenib, ME344, or phenformin
are available drugs for which the maximum tolerated doses are
already known. Dose-finding combination phase I trials with
drugs with already known maximum tolerated doses and toxic-
ities are relatively simple compared to trials involving combina-
tions of investigational agents. On the basis of our findings, we
are designing a phase I clinical trial exploring the safety and effi-
cacy of the combination of nintedanib plus phenformin.
EXPERIMENTAL PROCEDURES
Mouse Models
All animal experiments were approved by the CNIO (Spanish National Cancer
Research Centre) Ethics Committee and performed in accordance with the
guidelines stated in the International Guiding Principles for Biomedical
Research Involving Animals developed by the Council for International Organi-
zations of Medical Sciences. PyMT [FVB/N-Tg(MMTV-PyVT)634Mul/J] mice
were obtained from W. Muller. C57BL/6JOlaHsd were obtained from the
CNIO Animal House. Four- to 6-week-old female athymic nude mice (Hsd:
Athymic Nude-Foxn1nu) were purchased from Charles River Laboratories.
Pulm24 PDX was kindly provided by Dr. Manuel Hidalgo. Tumors were
implanted subcutaneously in the lower back of Athymic Nude-Foxn1nu, and
mouse–mouse passages were performed to obtain the experimental animal
cohorts as described previously.
For the syngenicmodel of LLC, cell suspensions (105 cells/100 ml) in 13PBS
were injected subcutaneously into 8-week-old C57BL/6JOlaHsd mice in both
flanks.
Animal Treatments
The treatment allocations were randomly assigned using computer-generated
random numbers (http://www.randomization.com/). The researcher perform-
ing tumor measurements was blinded to the treatment allocation. Treatment
with the different drugs was started at 7 weeks of age. B20-4.1.1 (Genentech)
was prepared in 1 3 PBS and administered at 5 mg/kg intraperitoneally twice
per week. Nintedanib (Boehringer-Ingelheim) and regorafenib (Bayer) were
administered at 85and10mg/kg/day, respectively, by oral gavage. Phenformin
(Sigma-Aldrich) was administered at 300 mg/kg/day in 5% sucrose in drinking
water. ME344 was administered at 50 mg/kg intraperitoneally three times per
week. Dovitinib (Novartis) was freshly prepared in pH 2.5 water and adminis-
tered by oral gavage at 40 mg/kg/day. Tamoxifen (Sigma-Aldrich) was admin-
istered daily by oral gavage (1.2 mg/kg/day) in 10% ethanol in sunflower oil.
Tumor Measurements and Treatment Combinations Effects
Tumor dimensions were measured once per week using calipers. Tumor
volumes were calculated using the formula V = (D 3 d2)/2 mm3, where D is
the largest diameter and d is the shortest diameter; all measurements were
in millimeters. All tumors arising in mammary glands were measured in each
animal. To calculate TGI, we used the following formula: TGI = [1  (TF/T0)A/
(TF/T0)V] 3 100, where TF is the time point analyzed, T0 is the initial time, A is
the corresponding drug, and V is the vehicle.
For treatment combinations, the thresholds for antagonistic, additive, or
synergistic effects were calculated as follows: TA = Fa + Fb(1  Fa), where Fa
is the relative TGI (from 0 to 1) value at a given time point for the first drug
and Fb is the relative TGI value at the same time point for the second drug.
Variations within ±15%of the additive threshold are considered to be the result
of additive drug interactions; combinations exerting <85% of the predicted
additive effect are considered indifferent (and below 70%, antagonistic); com-
binations exerting >115% of the predicted threshold for additive effect syner-
gistic. The effects of the combinations are calculated at the last time point
when the animals belonging to the treatment group that was first terminated
because of tumor growth among those compared were alive.
Tumor Processing
Animals were killed in a CO2 chamber, and tumors were dissected from the
front limb mammary fat pad. Depending on the procedure, the tumors were
fixed in 10% formalin solution and embedded in paraffin, snap-frozen in iso-
pentane, or OCT-embedded for cryopreservation (TissueTek; Sakura Finetek).
A slide stained with H&E was obtained for every tumor to spatially guide mac-
rodissection or microdissection procedures.
Micro Positron Emission Tomography with [18F]Fluorodeoxyglucose
Mice were anesthetized with a continuous flow of 1%–3% isoflurane/oxygen
mixture (2 l/min). The mice were injected into the tail vein with 500 mCi of
18F-FDG in a volume of 0.1 ml. Images were acquired using eXplore Vista
PET-CT (GE HC) 45 min after radiotracer injection, starting with the micro-
CT scan X-ray tube settings 40 kV and 300 mA; 400 projections were collected
in one full rotation of the gantry in approximately 10 min. MicroPET scans were
immediately performed at 15 min per bed, 30 min in total, to perform a whole-
body study. The microPET images were reconstructed using the three-dimen-
sional ordered subsets expectation-maximization reconstruction algorithm.
Regions of interest were drawn over breast tumors and quantitative evalua-
tions were performed using AMIDE software to obtain the standardized uptake
values (SUVs). The calculation for SUV is as follows:
SUV= tissue radioactivity concentrationðMBq=mlÞ=injected dose ðMBqÞ=
body weightðgÞ:
Statistics
The sample size for animal experiments was calculated as in the following
example: for tumor growth delay, the continuous variable under study is TGI,
and the objective is to test whether one treatment group versus another
show TGI. The null hypothesis is that TGI is the same across all treatment
groups, and the alternate hypothesis is that TGI is different across groups.
Parameters for vehicle-treated animals are known: median time to sacrifice is
46 days, and SD is 10.39 days. With a = 0.05 and a power of 80%, and
measuring at least one tumor per animal, the minimum number of animals
per group to detect at least a 30% variation (or 30% TGI), comparing growth
curves by ANOVA test, is 10. Assuming a methodological failure of 10%, we
treated 11 animals per group. Similar assumptions were made for other quan-
titative variables (i.e., PET-SUV). In all cases, the sample size was exceeded by
at least 20% to avoid ‘‘borderline’’ interpretations (rule for stopping data collec-
tion). No data or outliers were excluded from the analysis, besides animals that
were found dead for unknown reasons in the cage during treatment (approxi-
mately 1%–2% of the >5,000 animals used). Outliers, defined as more than 2
SDs away from the mean value, were included in all calculations in the high-
throughput studies. All experiments were performed aminimum of three times.
Mean values for two-way comparisons were determined using a t test.
Multiple comparisons involving more than two groups were performed with
statistically significant differences among experimental groups and were
assessed by one-way ANOVA with Tamhane’s adjustment. All tests were per-
formed using the program IBM SPSS statistics version 19, and p < 0.05 was
considered significant. All comparisons were two tailed. Parametric tests
were chosen because of the high number of tumors and animals per group
in all experiments. All data are expressed as means ± SEM, except the
metabolomic data (boxplots). Specific statistical methods for metabolomic,
phosphoproteomic, and transcriptomic data are reported in Supplemental
Experimental Procedures.
Other Procedures
Methods for proteomics, metabolomics, and genomics are included in
Supplemental Experimental Procedures. In addition, immunohistochemistry,
enzymohistochemistry, immunoblots, confocal microscopy, oxygen-con-
sumption assays, RT-PCR and genotyping (including primers), and plasma
determinations (ketone bodies and triglycerides), are described in Supple-
mental Experimental Procedures as well.
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